Plus Therapeutics Inc Financials
Plus Therapeutics Inc (PSTV) reported $5.2M in revenue for fiscal year 2025, down 10.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending remains larger than sales, while financing inflows—not operations—drive the latest balance-sheet repair.
The near match between FY2025 net loss of$22.4M and operating cash flow of-$20.8M indicates that reported losses are largely cash-based, not mainly non-cash accounting effects. Free cash flow nearly matched operating cash flow despite just$67K of capital expenditure, making day-to-day operations—not reinvestment—the dominant cash drain.
FY2025 R&D of
Equity moved from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Plus Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Plus Therapeutics Inc, and counted as zero in the overall score.
Not available for Plus Therapeutics Inc, and counted as zero in the overall score.
Plus Therapeutics Inc scores -45.51, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($26.6M) relative to total liabilities ($12.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Plus Therapeutics Inc passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Plus Therapeutics Inc reported a net loss of $22.4M while operations used $20.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Plus Therapeutics Inc reported an operating loss of $15.3M against $548K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Plus Therapeutics Inc generated $5.2M in revenue in fiscal year 2025. This represents a decrease of 10.5% from the prior year.
Plus Therapeutics Inc's EBITDA was -$14.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.5% from the prior year.
Plus Therapeutics Inc reported -$22.4M in net income in fiscal year 2025. This represents a decrease of 72.5% from the prior year.
Plus Therapeutics Inc earned -$0.29 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Plus Therapeutics Inc recorded an outflow of $20.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 94.8% from the prior year.
Plus Therapeutics Inc held $4.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Plus Therapeutics Inc's ROE was -560.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Plus Therapeutics Inc invested $8.4M in research and development in fiscal year 2025. This represents a decrease of 20.8% from the prior year.
Plus Therapeutics Inc invested $67K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 54.1% from the prior year.
Not reported for fiscal year 2025.
PSTV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2M | $5.2M-10.5% | $5.8M+18.5% | $4.9M | N/A | N/A | N/A | N/A | $3.7M+36.5% | $2.7M-42.2% | $4.7M-3.8% | $4.8M-2.3% | $5.0M-30.5% | $7.1M-18.2% | $8.7M+9.1% | $8.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.1M-12.9% | $1.3M-51.5% | $2.7M-14.8% | $3.2M+8.4% | $2.9M-14.1% | $3.4M-14.5% | $4.0M+4.2% | $3.8M |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $2.5M+1628.1% | $146K-92.5% | $1.9M+17.5% | $1.7M-17.9% | $2.0M-45.6% | $3.7M-21.4% | $4.7M+13.6% | $4.1M |
| R&D Expenses | $12.5M | $8.4M-20.8% | $10.6M+9.2% | $9.7M-0.1% | $9.7M+82.2% | $5.3M+97.1% | $2.7M-49.7% | $5.4M-2.9% | $5.5M+8.9% | $5.1M-68.7% | $16.2M-14.8% | $19.0M+25.8% | $15.1M-11.5% | $17.1M+25.2% | $13.6M+25.0% | $10.9M |
| SG&A Expenses | $18.1M | $12.1M+22.1% | $9.9M+16.3% | $8.5M-16.5% | $10.2M+49.4% | $6.9M+7.0% | $6.4M+21.1% | $5.3M-5.2% | $5.6M-16.7% | $6.7M-21.8% | $8.6M-12.3% | $9.8M-38.8% | $16.0M-0.5% | $16.0M+2.3% | $15.7M+6.4% | $14.7M |
| Operating Income | -$26.4M | -$15.3M-4.1% | -$14.7M-10.3% | -$13.3M+32.4% | -$19.7M-57.8% | -$12.5M-30.3% | -$9.6M-162.1% | -$3.7M+58.3% | -$8.8M+20.9% | -$11.1M+43.8% | -$19.7M-28.9% | -$15.3M+52.9% | -$32.4M-5.7% | -$30.7M-8.0% | -$28.4M+3.4% | -$29.4M |
| Interest Expense | N/A | $548K+206.1% | $179K-54.7% | $395K-44.4% | $711K-23.7% | $932K-15.8% | $1.1M-40.3% | $1.9M-3.5% | $1.9M-6.2% | $2.0M-20.9% | $2.6M-23.3% | $3.4M-22.7% | $4.4M+28.7% | $3.4M+0.3% | $3.4M+21.6% | $2.8M |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A | N/A | N/A |
| Net Income | -$26.1M | -$22.4M-72.5% | -$13.0M+2.5% | -$13.3M+34.3% | -$20.3M-51.3% | -$13.4M-62.6% | -$8.2M+24.3% | -$10.9M+13.8% | -$12.6M+44.3% | -$22.7M-2.9% | -$22.0M-17.6% | -$18.7M+49.8% | -$37.4M-42.8% | -$26.2M+18.9% | -$32.3M+0.5% | -$32.5M |
| EPS (Diluted) | — | -$0.29 | -$2.34 | -$4.24 | -$11.58 | -$1.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$0.61 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PSTV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $16.3M+146.1% | $6.6M-41.8% | $11.4M-52.3% | $23.9M+8.6% | $22.0M+81.6% | $12.1M-47.9% | $23.2M-3.2% | $24.0M-24.1% | $31.6M-8.7% | $34.6M-8.2% | $37.7M-2.6% | $38.7M-7.9% | $42.1M-2.8% | $43.3M-16.1% | $51.5M |
| Current Assets | $15.2M+188.5% | $5.3M-46.5% | $9.8M-54.9% | $21.8M+10.6% | $19.7M+115.0% | $9.2M-53.7% | $19.8M+105.5% | $9.6M-35.1% | $14.9M-20.7% | $18.7M-11.7% | $21.2M-2.0% | $21.7M-11.8% | $24.6M-27.7% | $34.0M-21.6% | $43.3M |
| Cash & Equivalents | $4.3M+5500.0% | $76K-99.1% | $8.6M-52.8% | $18.1M-1.5% | $18.4M+120.5% | $8.3M-52.4% | $17.6M+233.6% | $5.3M-44.9% | $9.6M-24.2% | $12.6M-12.1% | $14.3M-1.9% | $14.6M-5.7% | $15.5M-39.7% | $25.7M-30.3% | $36.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | $107K0.0% | $107K0.0% | $107K-97.1% | $3.7M-13.3% | $4.3M-11.0% | $4.8M+30.7% | $3.7M+16.3% | $3.2M-4.3% | $3.3M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $1.2M+556.7% | $178K+36.9% | $130K-89.5% | $1.2M+18.1% | $1.1M-15.4% | $1.2M-70.1% | $4.2M+5.8% | $3.9M+73.7% | $2.3M |
| Goodwill | $372K0.0% | $372K0.0% | $372K0.0% | $372K0.0% | $372K0.0% | $372K0.0% | $372K0.0% | $372K0.0% | $372K-90.5% | $3.9M0.0% | $3.9M0.0% | $3.9M0.0% | $3.9M0.0% | $3.9M0.0% | $3.9M |
| Total Liabilities | $12.3M-20.9% | $15.6M+22.3% | $12.7M-26.9% | $17.4M+56.3% | $11.1M+22.8% | $9.1M-58.9% | $22.1M+17.6% | $18.8M+0.8% | $18.6M-21.2% | $23.6M-7.3% | $25.5M-42.6% | $44.4M+14.1% | $38.9M+5.8% | $36.8M-11.5% | $41.6M |
| Current Liabilities | $12.3M-20.8% | $15.6M+45.0% | $10.7M-9.5% | $11.9M+101.9% | $5.9M-31.3% | $8.5M-41.1% | $14.5M-17.5% | $17.6M-4.6% | $18.4M+47.3% | $12.5M+48.2% | $8.4M-47.0% | $15.9M+6.8% | $14.9M-15.4% | $17.6M+125.2% | $7.8M |
| Long-Term Debt | N/A | N/A | N/A | $3.8M-24.4% | $5.0M | N/A | N/A | N/A | $0-100.0% | $11.0M-34.0% | $16.7M-7.5% | $18.0M-21.9% | $23.1M+79.0% | $12.9M-41.2% | $22.0M |
| Total Equity | $4.0M+144.7% | -$8.9M-563.9% | -$1.3M-120.9% | $6.4M-40.5% | $10.8M+257.5% | $3.0M+161.3% | $1.2M-77.8% | $5.2M-59.8% | $13.0M+18.3% | $11.0M-10.0% | $12.2M+314.1% | -$5.7M-282.1% | $3.1M-51.5% | $6.5M-35.1% | $9.9M |
| Retained Earnings | -$515.9M-4.5% | -$493.5M-2.7% | -$480.5M-2.9% | -$467.2M-4.5% | -$446.9M-3.1% | -$433.5M-1.9% | -$425.3M-2.6% | -$414.4M-3.1% | -$401.7M-6.0% | -$379.1M-6.2% | -$357.0M-5.5% | -$338.3M-12.4% | -$300.9M-9.5% | -$274.7M-13.3% | -$242.4M |
PSTV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$22.2M | -$20.8M-96.8% | -$10.6M+17.9% | -$12.9M+0.9% | -$13.0M-26.2% | -$10.3M-21.9% | -$8.4M-42.8% | -$5.9M+50.7% | -$12.0M+33.9% | -$18.1M+7.2% | -$19.5M+4.6% | -$20.5M+32.5% | -$30.3M+12.2% | -$34.6M-7.4% | -$32.2M+8.9% | -$35.3M |
| Capital Expenditures | $1.4M | $67K-54.1% | $146K-8.8% | $160K | N/A | N/A | N/A | $67K-49.6% | $133K-54.9% | $295K+340.3% | $67K-89.0% | $611K-20.0% | $764K+47.2% | $519K-56.9% | $1.2M+115.0% | $560K |
| Free Cash Flow | -$23.5M | -$20.8M-94.8% | -$10.7M+17.8% | -$13.0M | N/A | N/A | N/A | -$6.0M+50.7% | -$12.1M+34.3% | -$18.4M+6.0% | -$19.6M+7.0% | -$21.1M+32.2% | -$31.1M+11.4% | -$35.1M-5.0% | -$33.4M+6.9% | -$35.9M |
| Investing Cash Flow | -$2.9M | -$854K+79.2% | -$4.1M-2469.4% | -$160K+78.9% | -$759K-825.6% | -$82K+83.4% | -$493K-108.9% | $5.6M+4288.0% | -$133K+90.4% | -$1.4M | N/A | N/A | -$1.3M-136.4% | $3.7M+406.1% | -$1.2M-115.0% | -$560K |
| Financing Cash Flow | $25.3M | $30.3M+389.9% | $6.2M+79.6% | $3.4M-74.4% | $13.5M-34.1% | $20.4M+6500.0% | -$319K-102.5% | $12.6M+76.2% | $7.2M-57.4% | $16.8M | N/A | N/A | N/A | $20.8M-6.4% | $22.2M+10.2% | $20.1M |
| Share Buybacks | N/A | N/A | $374K+196.8% | $126K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PSTV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 68.7%+63.3pp | 5.4%-36.3pp | 41.7%+7.5pp | 34.2%-6.5pp | 40.6%-11.3pp | 52.0%-2.1pp | 54.1%+2.1pp | 51.9% |
| Operating Margin | -293.5% | -252.3% | -271.1% | N/A | N/A | N/A | N/A | -238.7% | -412.0% | -423.2% | -316.0% | -654.9% | -430.8% | -326.3% | -368.4% |
| Net Margin | -429.4% | -222.8% | -271.0% | N/A | N/A | N/A | N/A | -344.2% | -843.7% | -473.5% | -387.4% | -754.5% | -367.6% | -370.6% | -406.5% |
| Return on Equity | -560.2% | N/A | N/A | -314.6%-190.9pp | -123.6%+148.2pp | -271.9%+666.6pp | -938.5%-696.7pp | -241.8%-67.3pp | -174.5%+26.2pp | -200.7%-47.1pp | -153.6% | N/A | -835.8%-335.7pp | -500.1%-173.8pp | -326.3% |
| Return on Assets | -137.1%+58.5pp | -195.7%-78.7pp | -116.9%-32.0pp | -85.0%-24.0pp | -61.0%+7.1pp | -68.1%-21.2pp | -46.9%+5.8pp | -52.7%+19.1pp | -71.8%-8.1pp | -63.7%-14.0pp | -49.7%+46.8pp | -96.5%-34.3pp | -62.2%+12.4pp | -74.6%-11.7pp | -63.0% |
| Current Ratio | 1.23+0.9x | 0.34-0.6x | 0.92-0.9x | 1.84-1.5x | 3.36+2.3x | 1.07-0.3x | 1.37+0.8x | 0.55-0.3x | 0.81-0.7x | 1.50-1.0x | 2.52+1.2x | 1.36-0.3x | 1.65-0.3x | 1.93-3.6x | 5.54 |
| Debt-to-Equity | 3.09 | N/A | N/A | 0.59+0.1x | 0.46-2.5x | 2.99-16.0x | 19.02+15.4x | 3.59+3.6x | 0.00-1.0x | 1.00-0.4x | 1.37 | N/A | 7.38+5.4x | 2.00-0.2x | 2.21 |
| FCF Margin | -399.8% | -183.7% | -264.8% | N/A | N/A | N/A | N/A | -329.8% | -685.1% | -421.0% | -435.7% | -627.8% | -492.6% | -383.5% | -449.5% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Plus Therapeutics Inc Ranks
Frequently Asked Questions
What is Plus Therapeutics Inc's annual revenue?
Plus Therapeutics Inc (PSTV) reported $5.2M in total revenue for fiscal year 2025. This represents a -10.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Plus Therapeutics Inc's revenue growing?
Plus Therapeutics Inc (PSTV) revenue declined by 10.5% year-over-year, from $5.8M to $5.2M in fiscal year 2025.
Is Plus Therapeutics Inc profitable?
No, Plus Therapeutics Inc (PSTV) reported a net income of -$22.4M in fiscal year 2025.
What is Plus Therapeutics Inc's EBITDA?
Plus Therapeutics Inc (PSTV) had EBITDA of -$14.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Plus Therapeutics Inc's return on equity (ROE)?
Plus Therapeutics Inc (PSTV) has a return on equity of -560.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Plus Therapeutics Inc's free cash flow?
Plus Therapeutics Inc (PSTV) recorded an outflow of $20.8M in free cash flow during fiscal year 2025. This represents a -94.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Plus Therapeutics Inc's operating cash flow?
Plus Therapeutics Inc (PSTV) recorded an outflow of $20.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Plus Therapeutics Inc's total assets?
Plus Therapeutics Inc (PSTV) had $16.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Plus Therapeutics Inc's capital expenditures?
Plus Therapeutics Inc (PSTV) invested $67K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Plus Therapeutics Inc spend on research and development?
Plus Therapeutics Inc (PSTV) invested $8.4M in research and development during fiscal year 2025.
What is Plus Therapeutics Inc's current ratio?
Plus Therapeutics Inc (PSTV) had a current ratio of 1.23 as of fiscal year 2025, which is considered adequate.
What is Plus Therapeutics Inc's debt-to-equity ratio?
Plus Therapeutics Inc (PSTV) had a debt-to-equity ratio of 3.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Plus Therapeutics Inc's return on assets (ROA)?
Plus Therapeutics Inc (PSTV) had a return on assets of -137.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Plus Therapeutics Inc's Altman Z-Score?
Plus Therapeutics Inc (PSTV) has an Altman Z-Score of -45.51, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Plus Therapeutics Inc's Piotroski F-Score?
Plus Therapeutics Inc (PSTV) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Plus Therapeutics Inc's earnings high quality?
Plus Therapeutics Inc (PSTV) reported a net loss of $22.4M while operations used $20.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Plus Therapeutics Inc cover its interest payments?
Plus Therapeutics Inc (PSTV) reported an operating loss of $15.3M against $548K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Plus Therapeutics Inc?
Plus Therapeutics Inc (PSTV) scores 32 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.